CN1432365A - Antiviral veterinary drug injection and preparation method thereof - Google Patents
Antiviral veterinary drug injection and preparation method thereof Download PDFInfo
- Publication number
- CN1432365A CN1432365A CN 02100128 CN02100128A CN1432365A CN 1432365 A CN1432365 A CN 1432365A CN 02100128 CN02100128 CN 02100128 CN 02100128 A CN02100128 A CN 02100128A CN 1432365 A CN1432365 A CN 1432365A
- Authority
- CN
- China
- Prior art keywords
- preparation
- quality inspection
- injection
- content
- qualified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 19
- 239000007924 injection Substances 0.000 title claims abstract description 19
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000000273 veterinary drug Substances 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000007639 printing Methods 0.000 claims abstract 2
- 238000007689 inspection Methods 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 229930027917 kanamycin Natural products 0.000 claims description 6
- 229960000318 kanamycin Drugs 0.000 claims description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 6
- 229930182823 kanamycin A Natural products 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 230000003612 virological effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 2
- 238000012372 quality testing Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229940085771 feverall Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a new antiviral veterinary injection, which is prepared mainly from polyinosinic acid through the steps of blending, filtering, quality testing, encapsulating, sterilizing, quality testing, printing and packaging. Compared with the prior art, the traditional Chinese medicine composition has the advantages of high curative effect, safety, reliability, no toxicity, no harm, no residue, simple process, low cost and strong practicability. Can be used in the field of viral disease treatment, has obvious effect and is a good medicine for treating viral diseases.
Description
The present invention relates to a kind of veterinary antivirus injection and preparation method thereof.Relate to a kind of Western medicine aqueous injection and preparation method thereof specifically with broad-spectrum high efficacy antivirus action.The medicine that utilizes the spirit of this invention to produce can be used for the treatment of viral disease.
We know: viral diseases such as coronavirus property intestinal class, calf dysentery, cattle mucosa intestinal class, swine fever all respectively have certain sickness rate, and mortality rate height, even to this day, still there is not the good curing medicine both at home and abroad, so the treatment of viral disease has become the problem of having a headache the most on the veterinary clinic.Though some scholars suggestion is with the biological product treatment, biological product cost height yields poorly, can't mass production, and recurrence easily after the drug withdrawal in addition, overall cure rate is not high, and easily propagates other disease, should not promote the use of.So the medicine of research viral disease has become the task of top priority with Therapeutic Method.
Discover: after in the injection of producing according to spirit of the present invention injects body, can make the synthetic in vivo antiviral substance of animal, produce the broad-spectrum disease resistance toxic action, determined curative effect is the good medicine of treatment viral disease.
The present invention is through the effort of more than ten years, prescription and process study, stability experiment, pharmacological experiment, clinical experiment and clinical verification, middle trial production have been finished by the characteristics of veterinary drug injection, and put whole declaration materials in order by the requirement of the new veterinary drug of three classes, finished censorship declaration work.
The object of the present invention is to provide a kind of new antivirus veterinary aqueous injection and preparation method thereof.
The object of the present invention is achieved like this: it mainly forms this invention by polyinosinic acid and poly through operations such as allotment, filtration, embedding, sterilization, quality inspections---and the broad-spectrum high efficacy antiviral injection has another name called permanent promise injection.
Prescription of the present invention is:
Polyinosinic acid, poly, potassium dihydrogen phosphate, sodium hydrogen phosphate, kanamycin and water for injection, wherein kanamycin is a stabilizing agent, aqueous injection Chinese medicine content can be decided according to clinical needs.
The preparation method of antiviral aqueous injection of the present invention is:
1. allotment: at first prepare pH value and be 7.2 Diphosphonate buffer, after finishing, preparation adds an amount of kanamycin, it is an amount of to get this phosphate buffer, put into the polyinosinic acid and the poly of full dose, stirring makes it dissolving, then add an amount of above-mentioned Diphosphonate buffer that contains kanamycin again, make drug level be regulation content, standby;
2. filter: get above-mentioned reserve liquid, filter with No. 4 filter bulbs, also available continuous filter unit filters, and is standby;
3. quality inspection: by the laboratorian clarity, content etc. is checked, entered next procedure after qualified;
4. embedding: the peace bottle that cuts, justifies, washes, dries by the fire after qualified of learning from else's experience pours in this peace bottle above-mentioned reserve liquid and sealing by fusing on filling and sealing machine;
5. sterilization: with Pasteur's bacterium method or ultraviolet disinfection
6. quality inspection: by the laboratorian content, loading amount, character, clarity etc. are checked, entered next procedure after qualified;
7. lettering, packing: use the ink writer lettering, after packing, promptly get this invention---broad-spectrum high efficacy antiviral aqueous injection.
What deserves to be mentioned is: this medicine people medication is existing produces, but does not still have national standard, and the provincial standard of various places differs, and belongs to the new veterinary drug of three classes according to veterinary drug development gist of a document.This medicine raw material is easily purchased, and cost is low, the price height, and technology is very not complicated, and the development sequence height, has reached the level of commercially producing, and technology maturation is easy to implement, small investment, instant effect is fit to large, medium and small pharmaceutical factory and produces.
The present invention compared with prior art, its curative effect height, safe and reliable, nontoxic, harmless, noresidue, technology is simple, and is with low cost, practical.Can be used for viral disease treatment field, is the good medicine of viral disease treatment aspect.
Embodiment:
Getting potassium dihydrogen phosphate and sodium hydrogen phosphate, to prepare pH value in right amount be 7.2 Diphosphonate buffer 5000ml; Add successively;
1, polyinosinic acid 0.554g, poly 0.446g, kanamycin sulfate 5,000,000 units, mixing, standby;
2, get above-mentioned reserve liquid, be filtered to clarification with No. 4 filter sticks, standby;
3, quality inspection: by the laboratorian its character, content, clear degree etc. are checked, standby;
4, embedding: get above-mentioned reserve liquid and pouring on the filling and sealing machine in cutting, justify, wash, dry by the fire qualified peace bottle and sealing by fusing.
5, sterilization: the peace bottle of the medicine after the embedding was put into 80 ℃ of sterilization containers 30 minutes, also can be under normal pressure 100 ℃ 5 minutes, can finish sterilizing works;
6, quality inspection: by the laboratorian projects such as content, loading amount, character, clarity are checked, entered next procedure after qualified;
7, lettering: get the qualified product of chemical examination and on ink writer, finish lettering;
8, packing: finish the product of lettering operation, enter packaging process, after packing, obtain the present invention.
Claims (3)
1, a kind of antiviral aqueous injection, it is mainly made through technologies such as allotment, filtration, quality inspection, embedding, sterilization, quality inspection, printing packages by polyinosinic acid and poly etc.It is characterized in that dosage form is an injection.
2, antiviral aqueous injection according to claim 1, its feature is that also its preparation method is:
1. allotment: at first prepare pH value and be 7.2 Diphosphonate buffer, after finishing, preparation adds an amount of kanamycin, it is an amount of to get this phosphate buffer, put into the polyinosinic acid and the poly of full dose, stirring makes it dissolving, then add an amount of above-mentioned Diphosphonate buffer that contains kanamycin again, make drug level be regulation content, standby;
2. filter: get above-mentioned reserve liquid, filter with No. 4 filter bulbs, also available continuous filter unit filters, and is standby;
3. quality inspection: to clarity, content etc. check by the laboratorian, enter next procedure after qualified;
4. embedding: the peace bottle that cuts, justifies, washes, dries by the fire after qualified of learning from else's experience pours in this peace bottle above-mentioned reserve liquid and sealing by fusing on filling and sealing machine;
5. sterilization: with Pasteur's bacterium method or ultraviolet disinfection
6. quality inspection: by the laboratorian content, loading amount, character, clarity etc. are checked, entered next procedure after qualified;
7. lettering, packing: use the ink writer lettering, after packing, promptly get this invention---broad-spectrum high efficacy antiviral aqueous injection.
3, antiviral aqueous injection according to claim 1, its feature also is: technological process in the above-mentioned preparation method and injection Chinese medicine content do not limit the present invention.Also can adopt other suitable technology, use other adjuvant and use all appropriate drug concentration, but, all should be considered as within the scope of the present invention according to all improvement and variation that spirit of the present invention is carried out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02100128 CN1432365A (en) | 2002-01-09 | 2002-01-09 | Antiviral veterinary drug injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02100128 CN1432365A (en) | 2002-01-09 | 2002-01-09 | Antiviral veterinary drug injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1432365A true CN1432365A (en) | 2003-07-30 |
Family
ID=27626988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02100128 Pending CN1432365A (en) | 2002-01-09 | 2002-01-09 | Antiviral veterinary drug injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1432365A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101124014B (en) * | 2006-01-13 | 2013-05-22 | 依生生物制药(新加坡)私人有限公司 | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidylic acid based adjuvant |
| CN111116697A (en) * | 2019-12-27 | 2020-05-08 | 成都市海通药业有限公司 | Method for preparing polyinosinic cells |
-
2002
- 2002-01-09 CN CN 02100128 patent/CN1432365A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101124014B (en) * | 2006-01-13 | 2013-05-22 | 依生生物制药(新加坡)私人有限公司 | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidylic acid based adjuvant |
| CN111116697A (en) * | 2019-12-27 | 2020-05-08 | 成都市海通药业有限公司 | Method for preparing polyinosinic cells |
| CN111116697B (en) * | 2019-12-27 | 2023-08-29 | 成都市海通药业有限公司 | Method for preparing polyinosinic cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101919811A (en) | A kind of levetiracetam injection and preparation method thereof | |
| CN106890202A (en) | Purslane extract solution and preparation method thereof | |
| CN102440965B (en) | Esomeprazole sodium composition used for injection and its preparation method | |
| CN102335125A (en) | Adrenaline hydrochloride injection and preparation process thereof | |
| CN1432365A (en) | Antiviral veterinary drug injection and preparation method thereof | |
| CN108853003A (en) | A kind of Nifuratel-Nysfungin soft-capsule type suppository and preparation method thereof | |
| CN1663569A (en) | Fructose injection for cardiovascular medicine | |
| CN102813622A (en) | Ornidazole sodium chloride injection composition and preparation method thereof | |
| CN107569454B (en) | A kind of Olopatadine hydrochloride nasal spray and preparation method thereof | |
| CN101940596A (en) | New method for preparing cerebroprotein hydrolysate | |
| CN105012912A (en) | Compound norfloxacin sustained release tablet and preparation method | |
| CN103585172A (en) | Novel antiviral veterinary medicine injection and preparation method thereof | |
| TW546141B (en) | Low-molecular-weight heparins for use in the treatment of cerebral oedemas | |
| CN109646438A (en) | The application of demethyl coclaurine or its hydrochloride in preparation treatment rhinitis drug | |
| CN1069826C (en) | Freezing-dried tetracaine hydrochloride powder injection | |
| CN103284943A (en) | Novel method for preparing penehyclidine hydrochloride injection | |
| CN102716069A (en) | Injection liquid containing ibuprofen and preparation process of injection liquid | |
| CN107582898B (en) | A kind of medicinal composition for relieving cough and phlegm and its preparation method and use | |
| CN106039308A (en) | Preservative-free horse tetanus immune globulin preparation for injection and preparation method thereof | |
| CN112891434A (en) | Medicinal liquor for improving immunity and kidney function and preparation method thereof | |
| CN1062465C (en) | Shuangwujiangtang capsule for reducing blood sugar | |
| CN1110531A (en) | Dongbei forest-frog oral liquid and its preparation method | |
| CN1123664A (en) | Veterinary injection and its production | |
| CN102475731A (en) | Molecular vaccine raw material for treating children's (rotavirus, dysentery and malaria) disease | |
| CN1131558A (en) | Injection for animal and livestock emasculation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |